Every 10-Q that Meiragtx Holdings Plc (MGTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MGTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGTX filings page.
MeiraGTx Holdings plc reported a sharp swing to profitability for the six months ended June 30, 2026, driven by major partnering deals. Total revenue rose to $321.7 million from $5.6 million a year earlier, including $204.6 million of license revenue and $105.2 million of service revenue from related parties. Net income attributable to shareholders was $114.4 million versus a $78.8 million loss in 2025, and shareholders’ equity improved to $215.8 million from a deficit.
Cash, cash equivalents and restricted cash increased to $145.4 million, helped by equity raises and $100 million of royalty notes, while operating activities used $20.7 million of cash. Results include a $71.9 million equity-method loss from the new Reogen collaboration and a $25 million cash payment to reacquire full rights to the RPGR gene therapy from Janssen. Management states that current profitability is primarily due to non-recurring transactions and continues to expect substantial future losses as it advances its genetic medicines pipeline.
MeiraGTx Holdings plc reported Q1 2026 results with service revenue of $293,000 and a net loss of $46.3 million, compared with $40.0 million a year earlier. Operating expenses were $41.1 million, driven mainly by research and development and manufacturing costs.
Cash, cash equivalents and restricted cash totaled $73.8 million at March 31, 2026, and management expects liquidity, including an additional $100.0 million public equity raise completed in Q2 2026 and a tax incentive receivable, to fund operations for at least twelve months, including a $25.0 million debt repayment due in June.
The company highlighted several strategic transactions: a new asset purchase agreement with Janssen to reacquire its RPGR retinal gene therapy program for an upfront $25.0 million plus contingent milestones and royalties; a collaboration with Lilly that brought an upfront $75.0 million and potential milestones of over $400.0 million; and a broad AI-enabled neurology collaboration with Hologen, featuring a committed $200.0 million upfront payment (of which $105.0 million had been received by March 31, 2026) and up to an additional $230.0 million in program funding.
MeiraGTx Holdings (MGTX) reported a wider quarterly loss and tighter liquidity. For the three months ended September 30, 2025, total revenue was $410 thousand versus $10.9 million a year ago, driven by lower related-party service revenue. Operating expenses were $46.5 million, leading to a loss from operations of $46.1 million and a net loss of $50.5 million (basic and diluted loss per share $0.62).
Cash and cash equivalents fell to $14.8 million from $103.7 million at year-end, and shareholders’ equity moved to a $(40.6) million deficit as accumulated deficit reached $831.3 million. The company used $93.0 million in operating cash in the first nine months.
Management highlights pending strategic funding: an expected $200 million upfront from Hologen in Q4 2025 (with $28.0 million received during the period and an additional $22.0 million deposit in Q4 to date), up to $230 million of additional Hologen funding, and a $75.0 million upfront from Eli Lilly. Together with tax incentives and receivables, these are expected to fund operations for at least twelve months. Ordinary shares outstanding were 80,490,889 as of October 28, 2025.
MeiraGTx reported continued operating losses as it advances its gene-therapy pipeline and manufacturing business. For the six months ended June 30, 2025 the company recorded a $78.8 million net loss and used $80.8 million of cash from operations. Cash, cash equivalents and restricted cash totaled $34.4 million at June 30, 2025 and the balance sheet showed a $780.8 million accumulated deficit, leaving shareholders' equity at $3.0 million.
Strategically, MeiraGTx signed a March 9, 2025 collaboration with Hologen that contemplates a $200 million upfront payment and up to $230 million of additional funding; Hologen made a $6.0 million payment in June 2025 and an additional $17.0 million payment in the third quarter of 2025, and the parties expect the transaction to close in the third calendar quarter of 2025, subject to customary conditions. The company also retains a supply agreement and contingent payments tied to the prior asset sale to Johnson & Johnson (an initial $65.0 million upfront in 2023 and $60.0 million in milestones received in 2024, with up to $350.0 million of contingent consideration remaining). Management states available cash, receivables, the $17.0 million deposit received and anticipated remaining collaboration proceeds are expected to be sufficient to fund operations for at least the next twelve months.